ferrous gluconate has been researched along with losartan potassium in 3 studies
| Studies (ferrous gluconate) | Trials (ferrous gluconate) | Recent Studies (post-2010) (ferrous gluconate) | Studies (losartan potassium) | Trials (losartan potassium) | Recent Studies (post-2010) (losartan potassium) |
|---|---|---|---|---|---|
| 92 | 31 | 25 | 24,390 | 2,493 | 5,408 |
| Protein | Taxonomy | ferrous gluconate (IC50) | losartan potassium (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8.53 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0049 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0082 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.0082 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hörl, WH; Sunder-Plassmann, G | 1 |
| Davis, JM; Holtz, JB; Kuo, YH; Morris, K; Neibart, R; Torres, S | 1 |
| Calabrò, A; Campagna, MS; Franci, B; Nuti, R; Palazzuoli, A; Quatrini, I; Silverberg, DS; Spinelli, T | 1 |
1 review(s) available for ferrous gluconate and losartan potassium
| Article | Year |
|---|---|
Safety aspects of parenteral iron in patients with end-stage renal disease.
Topics: Anemia, Iron-Deficiency; Citric Acid; Drug Combinations; Drug Monitoring; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron Compounds; Iron Overload; Iron-Dextran Complex; Kidney Failure, Chronic; Sorbitol | 1997 |
2 trial(s) available for ferrous gluconate and losartan potassium
| Article | Year |
|---|---|
Intravenous iron following cardiac surgery does not increase the infection rate.
Topics: Aged; Anemia; Bacterial Infections; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Drug Therapy, Combination; Erythropoietin; Female; Ferrous Compounds; Hematinics; Humans; Injections, Intravenous; Male; Prospective Studies; Recombinant Proteins; Surgical Wound Infection; Time Factors | 2006 |
Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
Topics: Anemia; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Ferrous Compounds; Heart Failure; Hematinics; Hospitalization; Humans; Injections, Subcutaneous; Natriuretic Peptide, Brain; Pulmonary Artery; Recombinant Proteins; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Remodeling | 2009 |